The recent surge in psychedelic research—spurred by a Trump executive order and backed by influencers like Joe Rogan—has ignited a so-called psychedelic revolution. Yet this movement largely overlooks the needs and histories of people of color, raising questions about equity, access, and cultural sensitivity. Below, we explore the key issues through a Q&A format.

What is driving the current psychedelic revolution?

The revolution is fueled by a wave of clinical studies showing that substances like psilocybin, MDMA, and ketamine can treat PTSD, depression, and addiction. Celebrity endorsements—especially from Joe Rogan and a group of MAHA (Make America Healthy Again) loyalists—have amplified public interest. In 2025, President Trump signed an executive order to fast-track psychedelic research for therapeutic use. However, this momentum has been criticized for excluding communities of color, both in terms of who participates in research and who can access treatments.

Why are people of color being left behind in this revolution?

Multiple barriers exist. Historically, psychedelic research in the 1950s-60s involved mostly white participants, and the War on Drugs disproportionately criminalized drug use in Black and Latino communities. Today, high treatment costs (often exceeding $2,000 per session) and a lack of insurance coverage put therapy out of reach for many. Additionally, the clinical trials that drive FDA approvals typically enroll predominantly white, educated, and affluent volunteers. As a result, the benefits of psychedelic therapy are concentrated among those with resources, while minority communities face stigma, legal risks, and cultural misunderstandings within the therapeutic framework.

How do historical uses of psychedelics relate to this inequity?

Indigenous peoples from the Amazon to North America have used psychedelic plants like ayahuasca, peyote, and psilocybin mushrooms in sacred ceremonies for millennia—far predating Neanderthal use. Yet when Western researchers “discover” these compounds, the original cultures are often erased from the narrative. Furthermore, modern clinical settings strip away the communal, ritualistic context. Communities of color who practice these traditions are rarely consulted or compensated by the multibillion-dollar psychedelic industry, leading to accusations of cultural appropriation and biopiracy.

What role does the legal system play in marginalizing people of color?

Despite the clinical promise of psychedelics, they remain illegal under federal law. This creates a two-tier system: wealthy, predominantly white individuals can afford legal treatments in regulated settings (e.g., Oregon’s psilocybin program), while people of color in low-income neighborhoods risk arrest for possession. Arrests for psychedelics have increased in some cities, with Black and Latino individuals disproportionately affected. Unless decriminalization and legal access are paired with sentencing reform and community reinvestment, the revolution may deepen existing disparities.

What steps can researchers take to make studies more inclusive?

First, recruitment strategies must go beyond university campuses and online ads. Partnering with community health centers, churches, and cultural organizations in minority neighborhoods can build trust. Researchers should also hire diverse staff and include representatives from underrepresented groups in study design. Offering flexible dosing protocols (e.g., lower costs, shorter sessions) and addressing barriers like transportation, childcare, and language access are crucial. Finally, prioritizing conditions that disproportionately affect people of color—such as racial trauma, chronic pain from poverty, and substance use disorders—would ensure findings are relevant.

How can we ensure psychedelic therapy becomes truly equitable?

Equity requires systemic changes: expanding Medicaid coverage for psychedelic treatments, funding community-based clinics in underserved areas, and creating nonprofit models to keep costs low. Policymakers should pardon past convictions for psychedelic use and reinvest tax revenues into affected communities. Training more therapists of color and integrating Indigenous wisdom into clinical guidelines would also help. As the revolution accelerates, it’s vital to ask: Who is this for? Without deliberate focus on racial justice, the psychedelic renaissance will remain a privilege, not a common good.